Seres Therapeutics
Source-claim record: this page may be based on an automated extraction. The figure may describe a plan, an aggregate or overlapping coverage and has not necessarily been independently verified as a completed layoff.
Reported figure
110
(41%)
Reported or extracted reason
Restructuring after setbacks in its ulcerative colitis drug program
🔮 Oracle Verdict
This layoff has not yet been scored by the Oracle.
Source provenance
https://www.masslive.com/business/2026/10/mass-biotech-company-to-lay-off-almost…via Google Alerts RSS